The Ups and Downs of GLP-1 Drugs: Benefits Fade When Treatment Stops
Semaglutide and other glucagon-like peptide-1 (GLP-1) receptor agonists have garnered significant attention for their effectiveness in weight management and treatment of type 2 diabetes. Initially hailed as “miracle drugs” due to potential benefits extending beyond these core uses – including reduced risk of cardiovascular disease, cognitive impairment, and even addiction – recent research suggests these advantages may be short-lived once treatment is discontinued. Access to these medications remains a challenge due to cost, availability, and side effects.
Cardiovascular Benefits Disappear After Discontinuation
A study published in BMJ Medicine analyzed data from over 333,000 adults with diabetes over a three-year period. Researchers at the Washington University School of Medicine found that consistent treatment with a GLP-1 drug, such as Ozempic (semaglutide), was associated with an 18% lower risk of cardiovascular disease. This confirms previous research highlighting the cardiovascular benefits of these medications.
However, the study revealed a concerning trend: stopping treatment, even for a relatively short period of six months, increased the risk of a major cardiovascular event by up to 8%. For those who discontinued use for one to two years, the risk increased by 22%, effectively negating the protective effects previously gained. Epidemiologist Ziyad Al-Aly described this phenomenon as a “metabolic shock,” noting that building cardiovascular protection takes years, but it can be lost much more quickly as reported by CNBC.
Beyond Cardiovascular Health: Weight Regain and Other Reversal of Benefits
Weight regain is the most noticeable effect of stopping GLP-1 drugs, as appetite returns. However, Al-Aly’s research indicates other adverse effects occur, including a resurgence of inflammation, increased blood pressure, and elevated cholesterol levels. The study suggests that interruptions in treatment can leave “lasting scars,” as patients may not fully recover the initial benefits of the drug.
The research highlighted that a significant proportion of patients discontinue or interrupt treatment. During the study period, 26% of users stopped taking the medication completely, while 23% experienced breaks of at least six months before resuming.
Challenges with GLP-1 Drug Access and Side Effects
GLP-1 drugs are not without their drawbacks. Common side effects include nausea, affecting approximately half of patients at the start of treatment, with less frequent occurrences of vomiting and diarrhea. The high demand for these drugs, coupled with limited production, often leads to shortages in pharmacies.
The FDA has also issued warnings regarding compounded versions of semaglutide and tirzepatide, emphasizing that these unapproved versions do not undergo the same rigorous safety and quality checks as FDA-approved drugs as detailed on the FDA website. Improper storage during shipping can also compromise the quality of compounded drugs, as these injectable medications require refrigeration.
Semaglutide is sold under various brand names, including Mounjaro, Ozempic, Rybelsus, and Wegovy. While Wegovy is the only one FDA-approved as an anti-obesity medication, other medications are often prescribed “off-label” for weight loss according to the Alabama Board of Medical Examiners.
Key Takeaways
- GLP-1 drugs offer cardiovascular benefits while being taken consistently.
- These benefits can be rapidly lost upon discontinuation, even after short interruptions.
- Weight regain and other negative health markers often return when treatment stops.
- Access to GLP-1 drugs can be limited by cost, availability, and side effects.
- Compounded versions of these drugs carry additional risks due to lack of FDA oversight.